The display and use of drug information on this site is subject to express terms of use. By continuing to view the drug information, you agree to abide by such terms ...

LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global angina pectoris drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021.

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...

Add Yahoo as a preferred source to see more of our stories on Google. If angina pectoris – pain, pressure or tightness and shortness of breath – suddenly occurs even at rest, this can indicate an ...

The goals of treatment are to decrease the frequency of angina, increase longevity, and improve patients' QOL. Management of risk factors is an essential component of this therapy. Also important is ...

When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...

Angina pectoris, often shortened to angina, is chest pain or discomfort caused by reduced blood flow to the heart and most commonly -- but not always -- a symptom of coronary artery disease (CAD). The ...